Skip to main content
. 2018 Oct 10;13(10):e0204334. doi: 10.1371/journal.pone.0204334

Fig 3. Survival prediction of patients with cervical cancer by FIGO staging system and the expression level of serum CTC or SCC.

Fig 3

(A) The disease-free survival (DFS) curves of patients with positive and negative expression level of serum CTC (P < 0.0001). (B) The DFS curves of patients with positive and negative expression level of serum SCC (P = 0.0004). (C) DFS outcomes of patients with cervical cancer were predicted by FIGO staging system (Stage I vs. II, P = 0.0542; Stage II vs. III, P = 0.0097). (D) DFS outcomes of patients with cervical cancer were predicted by the combined serum CTC and SCC expression levels, which show that the combined risk model significantly improves survival prediction of patients (Group I, II and III represent low-risk, intermediate-risk and high-risk group, respectively. Group I vs. II, P = 0.0119; Group II vs. III, P = 0.0019).